ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LFCR vs ABBV // EV/EBITDA & P/E VALUATION

Lifecore Biomedical Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LFCR 1 — ABBV 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFCR VS. ABBV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LFCR ABBV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 70.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — 29.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 33.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.47% — TIE /fcf-yield <GO>
Operating Margin — 24.60% — TIE /operating-margins <GO>
Net Profit Margin — 6.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — 8.60% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.27% -2.27 ABBV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 7/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 65.4 65.1 +0.33 LFCR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 113.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $246.8M $513.86B -$513.61B ABBV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LFCR REV ABBV REV LFCR GROSS % ABBV GROSS % LFCR FCF ABBV FCF
FY 2025 $0 $61.16B — 70.2% — $17.82B
FY 2024 $128.9M $56.33B 31.3% 70.0% -$13.6M $17.83B
FY 2023 $0 $54.32B — — $257.0K $20.39B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFCR // BETA —
ABBV // BETA 1.15